Church & Dwight Co Inc (CHD)
Fair bewertetFundamental
67
Kurs
$94.22
Marktkapitalisierung
$22.68B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates in three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers baking soda, cat litters, laundry detergents, carpet deodorizers, and other baking soda-based products under the ARM & HAMMER brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; dry shampoos under the BATISTE brand; water flossers under the WATERPIK brand; oral care products under the THERABREATH brand; acne treatment products under the HERO brand; hand sanitizers under the TOUCHLAND brand; and condoms, lubricants, and vibrators under the TROJAN brand. It also provides home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; and cold shortening and relief products under the ZICAM brand. In addition, the company's specialty products include animal and food productivity products, such as ARM & HAMMER baking soda as a feed additive to help dairy cow; BIO-CHLOR and FERMENTEN used to reduce health issues associated with calving, as well as needed protein; CELMANAX refined functional carbohydrate, a yeast-based prebiotic; and CERTILLUS a probiotics products used in the poultry, dairy, beef, and swine industries. Additionally, it offers sodium bicarbonate; and cleaning and deodorizing products. The company sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. Church & Dwight Co., Inc. was founded in 1846 and is headquartered in Ewing, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
P&G is the first competitor named in Church & Dwight's own 10-K and fights for the same US shelf space in laundry detergent (Tide versus Arm & Hammer and Xtra), oral care and personal care.
Clorox is the closest rival by size and profile, competing on the same US household aisle in laundry additives, cleaners and cat litter (Fresh Step versus Arm & Hammer).
Colgate-Palmolive competes head-on in oral care against Arm & Hammer toothpaste, Spinbrush and TheraBreath, and in home care and pet products sold through the same retailers.
Kenvue competes in consumer self-care, where its Listerine, Neutrogena and cold-and-allergy brands sit against TheraBreath, Hero acne treatment and Zicam.
Reckitt competes across cleaning and health-and-hygiene categories where Church & Dwight also sells, from surface cleaners to sexual wellness products rivaling Trojan.
Unilever competes in personal care and home care worldwide, with dry shampoo, deodorant and laundry brands aimed at the same shoppers as Batiste and Arm & Hammer.
Bilanz & Liquidität
Umsatz
$6.23B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$745M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$1.09B
Gesamtes Eigenkapital
$4.00B
Gesamtverbindlichkeiten
$4.91B
Current Ratio
1.15
Zinsdeckungsgrad
11.26
Schulden/EBITDA
1.87
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$80.51
Aktueller Kurs
$94.22
Sicherheitsmarge
-17.0%
Innerer-Wert-Spanne
$56.29 - $104.72
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
30.30
ROE
18.4%
P/B-Verhältnis
5.14
P/FCF
20.75
Bruttomarge
45.6%
ROIC
11.1%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
11.1%
WACC
7.5%
ROIC − WACC
+3.5 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (19)
- EPS shows upward trend
- Price CAGR 7.86%
- ROIC 11.0%
- Gross Margin 45.6%
- P/FCF 20.75
- Debt/Equity ratio
- Operating Margin 17.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 17.8%
- Analyst Consensus 50% Buy
- Earnings Quality (OCF/NI) 1.65
- Share Dilution -1.2%
- Net Margin Trend 12.0% vs 8.7%
- Piotroski F-Score 6/9
Nicht bestanden (7)
- EPS CAGR 0.49%
- P/B Ratio 5.14
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.8%
- Earnings Surprise avg 2.5%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Richard A. Dierker | President, CEO & Director | 45 |
| Mr. Lee B. McChesney | CFO & Executive VP | 53 |
| Mr. Patrick D. de Maynadier Esq., J.D. | Executive VP, General Counsel & Secretary | 65 |
| Mr. Michael G. Read | Executive Vice President of International | 50 |
| Mr. Charles R. Raup | Executive VP & President of US Domestic | 57 |
| Mr. Joseph James Longo | VP, Chief Accounting Officer & Corporate Controller | 54 |
| Mr. Carlos G. Linares | Executive VP, CTO & Global New Product Innovation | 61 |
| Ms. Stacey Ramstedt | Senior VP & Chief Marketing Officer | - |
| Ms. Rene M. Hemsey | Executive VP & Chief Human Resources Officer | 57 |
| Mr. Brian Buchert | Executive VP of Strategy, M&A and Business Partnerships | - |
Prüfungsrisiko
4
Vorstandsrisiko
4
Vergütungsrisiko
2
Aktionärsrechterisiko
5
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-12
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-31
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-31
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for CHD, sourced from Markets Gazette.